Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%

Posted on by

JINAN, China, Dec. 6, 2023 /PRNewswire/ — Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.